Initial- and re-treatment effectiveness of glecaprevir and pibrentasvir for Japanese patients with chronic hepatitis C virus-genotype 1/2/3 infections.

Hitomi SezakiFumitaka SuzukiTetsuya HosakaShunichirou FujiyamaYusuke KawamuraNorio AkutaMasahiro KobayashiYoshiyuki SuzukiSatoshi SaitohYasuji AraseKenji IkedaMariko KobayashiHiromitsu Kumada

Published in: Journal of gastroenterology (2019)

Initial and re-treatment with GLE/PIB are effective and safe for Japanese patients with HCV-1/2/3 in real-life settings. Further studies are required to elucidate the mechanism underlying treatment failures of GLE/PIB to completely eradicate HCV worldwide.

Keyphrases

hepatitis c virus
randomized controlled trial
human immunodeficiency virus
systematic review
combination therapy
computed tomography
pet imaging
antiretroviral therapy
smoking cessation